Cellectar Biosciences, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 21.58 million compared to USD 8.58 million a year ago. Basic loss per share from continuing operations was USD 0.74 compared to USD 0.76 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.895 USD | -1.86% | -2.20% | +4.51% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.51% | 104M | |
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+17.02% | 246B | |
+9.26% | 213B | |
-4.21% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- CLRB Stock
- News Cellectar Biosciences, Inc.
- Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024